Skip to main content
. 2009 Apr 22;47(6):1942–1946. doi: 10.1128/JCM.02434-08

TABLE 3.

In vitro antifungal agent susceptibilities of Candida isolates collected by the SENTRY Program in 2006 to 2007

Species (no. tested) No. (%) of isolates or MIC50/90 in μg/ml (% susceptible)a
North America Europe Latin America
All Candida spp. 726 (50.1) 429 (29.6) 274 (18.9)
    Anidulafungin 0.03/2 (98.9) 0.03/1 (99.3) 0.03/1 (98.5)
    Caspofungin 0.12/0.5 (99.7) 0.12/0.5 (100.0) 0.12/0.5 (99.6)
    Amphotericin B 0.5/1 (99.9) 0.5/1 (99.5) 1/1 (98.9)
    5-FC ≤0.5/≤0.5 (95.7) ≤0.5/≤0.5 (95.3) ≤0.5/≤0.5 (97.1)
    Fluconazole ≤0.5/8 (91.3) ≤0.5/8 (94.4) ≤0.5/2 (97.1)
    Itraconazole 0.06/1 (64.9) 0.06/1 (72.3) 0.06/0.5 (68.6)
    Posaconazole ≤0.06/1 ≤0.06/1 ≤0.06/0.25
    Voriconazole ≤0.06/0.25 (97.9) ≤0.06/0.25 (98.4) ≤0.06/≤0.06 (99.3)
C. albicans 377 (48.9) 260 (33.7) 126 (16.3)
    Anidulafungin 0.015/0.06 (100.0) 0.015/0.06 (100.0) 0.015/0.06 (100.0)
    Caspofungin 0.12/0.25 (100.0) 0.12/0.25 (100.0) 0.12/0.25 (100.0)
    Amphotericin B 0.5/1 (100.0) 0.5/1 (100.0) 0.5/1 (100.0)
    5-FC ≤0.5/≤0.5 (96.8) ≤0.5/≤0.5 (98.8) ≤0.5/≤0.5 (99.2)
    Fluconazole ≤0.5/≤0.5 (99.5) ≤0.5/≤0.5 (100.0) ≤0.5/≤0.5(100.0)
    Itraconazole 0.03/0.12 (97.3) 0.03/0.06 (98.1) 0.03/0.12 (97.6)
    Posaconazole ≤0.06/0.12 ≤0.06/≤0.06 ≤0.06/0.12
    Voriconazole ≤0.06/≤0.06 (100.0) ≤0.06/≤0.06 (100.0) ≤0.06/≤0.06 (100.0)
C. parapsilosis 122 (51.3) 53 (22.3) 60 (25.2)
    Anidulafungin 2/2 (93.4) 2/2 (94.3) 1/2 (98.3)
    Caspofungin 0.5/1 (99.2) 0.5/1 (100.0) 0.5/1 (100.0)
    Amphotericin B 1/1 (100.0) 1/1 (100.0) 1/1 (100.0)
    5-FC ≤0.5/≤0.5 (99.2) ≤0.5/≤0.5 (100.0) ≤0.5/≤0.5 (96.7)
    Fluconazole 1/4 (95.9) 1/2 (100.0) 1/4 (95.0)
    Itraconazole 0.25/0.5 (43.4) 0.25/0.25 (43.4) 0.25/0.5 (30.0)
    Posaconazole 0.12/0.25 0.12/0.25 0.12/0.25
    Voriconazole ≤0.06/0.12 (100.0) ≤0.06/≤0.06(100.0) ≤0.06/0.12 (98.3)
C. glabrata 133 (65.8) 57 (28.2) 11 (0.05)
    Anidulafungin 0.06/0.12 (100.0) 0.06/0.12 (100.0) 0.06/0.12 (100.0)
    Caspofungin 0.12/0.25 (100.0) 0.25/0.25 (100.0) 0.25/0.5 (100.0)
    Amphotericin B 1/1 (100.0) 1/1 (100.0) 1/1 (100.0)
    5-FC ≤0.5/≤0.5 (100.0) ≤0.5/≤0.5 (100.0) ≤0.5/≤0.5 (100.0)
    Fluconazole 8/>64 (71.4) 8/16 (78.9) 4/16 (81.8)
    Itraconazole 1/>2 (2.3) 1/>2 (5.3) 1/2 (9.1)
    Posaconazole 1/4 1/4 0.5/1
    Voriconazole 0.25/2 (88.7) 0.25/1 (93.0) 0.12/0.5 (90.9)
C. tropicalis 53 (33.7) 36 (22.9) 62 (39.5)
    Anidulafungin 0.03/0.06 (100.0) 0.03/0.6 (100.0) 0.03/0.06 (100.0)
    Caspofungin 0.12/0.5 (100.0) 0.12/0.25 (100.0) 0.12/0.5 (100.0)
    Amphotericin B 1/1 (100.0) 1/1 (100.0) 1/1 (95.2)
    5-FC ≤0.5/≤0.5 (96.2) ≤0.5/≤0.5 (91.7) ≤0.5/≤0.5 (95.2)
    Fluconazole ≤0.5/1 (100.0) ≤0.5/1 (97.2) ≤0.5/≤0.5 (100.0)
    Itraconazole 0.12/0.5 (62.3) 0.12/0.5 (72.2) 0.12/0.5 (66.1)
    Posaconazole 0.12/0.25 ≤0.06/0.25 0.12/0.25
    Voriconazole ≤0.06/≤0.06 (100.0) ≤0.06/≤0.06 (100.0) ≤0.06/≤0.06 (100.0)
a

The breakpoint criteria used are those of the CLSI (2008). When testing amphotericin B, a susceptibility breakpoint of ≤1 μg/ml was used. No results are shown for categories with <10 isolates.